Therefore, the reasonable sensitivity (0.72 vs 0.89) and high specificity (0.88 vs 0.60) of PAX1 methylation make it a promising predictive marker of the short-term efficacy of CCRT in cervical cancer, and combining it with MRI may further enhance the accuracy of therapeutic monitoring. This evidence concerns the gene PAX1 and cervical carcinoma.